CYTK
Income statement / Annual
Last year (2024), Cytokinetics, Incorporated's total revenue was $18.47 M,
an increase of 145.34% from the previous year.
In 2024, Cytokinetics, Incorporated's net income was -$589.53 M.
See Cytokinetics, Incorporated,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$18.47 M |
$7.53 M |
$94.59 M |
$70.43 M |
$55.83 M |
$26.87 M |
$31.50 M |
$13.37 M |
$106.41 M |
$28.66 M |
| Cost of Revenue |
$0.00
|
$330.12 M
|
$240.81 M
|
$159.94 M
|
$96.95 M
|
$86.13 M
|
$89.14 M
|
$90.30 M
|
$59.90 M
|
$46.40 M
|
| Gross Profit |
$18.47 M
|
-$322.59 M
|
-$146.23 M
|
-$89.51 M
|
-$41.12 M
|
-$59.26 M
|
-$57.63 M
|
-$76.93 M
|
$46.51 M
|
-$17.74 M
|
| Gross Profit Ratio |
1
|
-42.84
|
-1.55
|
-1.27
|
-0.74
|
-2.21
|
-1.83
|
-5.75
|
0.44
|
-0.62
|
| Research and Development Expenses |
$339.41 M
|
$0.00
|
$6.59 M
|
$159.94 M
|
$96.95 M
|
$86.13 M
|
$89.14 M
|
$90.30 M
|
$59.90 M
|
$46.40 M
|
| General & Administrative Expenses |
$215.31 M
|
$173.61 M
|
$177.98 M
|
$96.80 M
|
$52.82 M
|
$39.61 M
|
$31.28 M
|
$36.47 M
|
$27.82 M
|
$19.67 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$215.31 M
|
$173.61 M
|
$177.98 M
|
$96.80 M
|
$52.82 M
|
$39.61 M
|
$31.28 M
|
$36.47 M
|
$27.82 M
|
$19.67 M
|
| Other Expenses |
$0.00
|
$0.00
|
-$6.59 M
|
-$159.94 M
|
-$96.95 M
|
-$86.13 M
|
$0.00
|
$0.00
|
$58.66 M
|
$31.73 M
|
| Operating Expenses |
$554.72 M
|
$173.61 M
|
$177.98 M
|
$96.80 M
|
$52.82 M
|
$39.61 M
|
$31.28 M
|
$36.47 M
|
$27.82 M
|
$19.67 M
|
| Cost And Expenses |
$554.72 M
|
$503.74 M
|
$418.79 M
|
$256.74 M
|
$149.77 M
|
$125.74 M
|
$120.42 M
|
$126.76 M
|
$87.72 M
|
$66.07 M
|
| Interest Income |
$51.53 M
|
$27.63 M
|
$11.34 M
|
$331,000.00
|
$5.33 M
|
$4.54 M
|
$4.19 M
|
$2.60 M
|
$0.00
|
$0.00
|
| Interest Expense |
$86.51 M
|
$57.67 M
|
$51.16 M
|
$29.33 M
|
$38.68 M
|
$27.36 M
|
$21.56 M
|
$17.00 M
|
$2.23 M
|
$94,000.00
|
| Depreciation & Amortization |
$9.53 M
|
$11.89 M
|
$8.40 M
|
$9.64 M
|
$1.83 M
|
$1.29 M
|
$1.24 M
|
$1.90 M
|
$741,000.00
|
$589,000.00
|
| EBITDA |
-$493.48 M |
-$456.68 M |
-$329.40 M |
-$176.35 M |
-$86.78 M |
-$93.04 M |
-$83.49 M |
-$108.89 M |
$14.93 M |
-$36.66 M |
| EBITDA Ratio |
-26.71
|
-60.65
|
-3.31
|
-2.64
|
-1.59
|
-3.46
|
-2.69
|
-8.29
|
0.18
|
-1.31
|
| Operating Income Ratio |
-29.03
|
-65.9
|
-3.43
|
-2.65
|
-1.68
|
-3.68
|
-2.82
|
-8.48
|
0.18
|
-1.31
|
| Total Other Income/Expenses Net |
-$53.28 M
|
-$30.04 M
|
-$64.75 M
|
-$29.00 M
|
-$33.35 M
|
-$22.83 M
|
-$17.37 M
|
-$14.39 M
|
-$2.23 M
|
-$94,000.00
|
| Income Before Tax |
-$589.53 M
|
-$526.24 M
|
-$388.96 M
|
-$215.31 M
|
-$127.29 M
|
-$121.69 M
|
-$106.29 M
|
-$127.79 M
|
$16.45 M
|
-$37.50 M
|
| Income Before Tax Ratio |
-31.91
|
-69.89
|
-4.11
|
-3.06
|
-2.28
|
-4.53
|
-3.37
|
-9.56
|
0.15
|
-1.31
|
| Income Tax Expense |
$0.00
|
$0.00
|
$13.60 M
|
$27.06 M
|
$36.85 M
|
$27.36 M
|
$4.19 M
|
$682,000.00
|
-$741,000.00
|
-$589,000.00
|
| Net Income |
-$589.53 M
|
-$526.24 M
|
-$402.55 M
|
-$242.37 M
|
-$164.14 M
|
-$149.05 M
|
-$106.29 M
|
-$127.79 M
|
$16.45 M
|
-$37.50 M
|
| Net Income Ratio |
-31.91
|
-69.89
|
-4.26
|
-3.44
|
-2.94
|
-5.55
|
-3.37
|
-9.56
|
0.15
|
-1.31
|
| EPS |
-5.26 |
-5.45 |
-4.48 |
-3.15 |
-2.54 |
-2.59 |
-1.95 |
-2.59 |
0.41 |
-0.97 |
| EPS Diluted |
-5.26 |
-5.45 |
-4.48 |
-3.15 |
-2.54 |
-2.59 |
-1.95 |
-2.59 |
0.39 |
-0.97 |
| Weighted Average Shares Out |
$111.98 M
|
$96.52 M
|
$89.83 M
|
$76.89 M
|
$64.52 M
|
$57.58 M
|
$54.42 M
|
$49.40 M
|
$39.94 M
|
$38.66 M
|
| Weighted Average Shares Out Diluted |
$111.98 M
|
$96.52 M
|
$89.83 M
|
$76.89 M
|
$64.52 M
|
$57.58 M
|
$54.42 M
|
$49.40 M
|
$42.56 M
|
$38.81 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
